PathGen raises funding from East Ventures and Royal Group Indonesia, making early disease detection and precision medicine more accessible
PathGen or PathGen Diagnostik Teknologi, an Indonesia-based healthcare biotechnology startup specializing in molecular testing solutions, has raised funding from East Ventures and Royal Group Indonesia
Genetic testing: Leading the way in preventive care for Southeast Asia
In a region plagued by diseases such as heart disease, stroke, cancer, diabetes and neonatal deaths, NalaGenetics is taking a stand. As a prominent provider of genetic testing solutions, this pioneering company is on a mission to combat these ailments and improve patient outcomes in Southeast Asia.
Rising biotech innovations to address Indonesia’s healthcare problems
With an over 270 million population, Indonesia remains an emerging medical market, supported by the surge of healthcare awareness demanded by the rising middle-income community. However, the country has faced chronic problems as the pandemic unveils shortcomings and an elevated sense of urgency to develop a more resilient healthcare system and innovations.